FMP
BELLUS Health Inc.
BLU.TO
TSX
Inactive Equity
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
19.48 CAD
-0.02 (-0.103%)
About
ceo
Mr. Roberto Francesco Bellini
sector
Healthcare
industry
Biotechnology
website
https://www.bellushealth.com
exchange
TSX
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
CIK
N/A
ISIN
N/A
CUSIP
N/A
Address
275 Armand-Frappier Boulevard
Phone
14506804500
Country
CA
Employee
74
IPO Date
Jun 22, 2000
Summary
CIK
-
Exchange
TSX
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
-
Country
CA
Price
19.48
Beta
-0.28
Volume Avg.
69.41k
Market Cap
2.47B
Shares
-
52-Week
8.58-19.9
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-20.29
P/B
-
Website
https://www.bellushealth.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BLU.TO News
It looks like there's no news available.
